Company Overview of Watson Pharma, Inc.
Watson Pharma, Inc. operates as a developer, manufacturer, and marketer of generic pharmaceutical products. It offers solid dosage and sterile dosage generic products. Watson Pharma, Inc. was formerly known as Schein Pharmaceutical, Inc. and changed its name to Watson Pharma, Inc. in August 2000. The company was founded in 1931 and is based in Florham Park, New Jersey. As of August 28, 2000, Watson Pharma, Inc. operates as a subsidiary of Actavis, Inc.
100 Campus Drive
Florham Park, NJ 07932
Founded in 1931
Key Executives for Watson Pharma, Inc.
Chairman and Chief Executive Officer
President and Chief Operating Officer and Director
Executive Vice President - Corporate Affairs
Senior Vice President - Strategic Development
Senior Vice President of Technical Operations
Compensation as of Fiscal Year 2013.
Watson Pharma, Inc. Key Developments
Shire Wins Patent Trial Against Watson Concerning LIALDA(R)
May 9 13
Shire plc announced that its subsidiary, Shire Development LLC, has prevailed in its litigation against Watson Pharmaceuticals Inc., Watson Laboratories, Inc.-Florida, Watson Pharma, Inc. and Watson Laboratories, Inc. in connection with their Abbreviated New Drug Application for a generic version of Shire's LIALDA(R) (mesalamine) delayed release tablets for the induction of remission in adults with active, mild to moderate ulcerative colitis and for the maintenance of remission of ulcerative colitis. Following a five day bench trial in the Southern District of Florida, Judge Middlebrooks issued a ruling upholding the validity of the patent covering LIALDA, US Patent No. 6,773,720, and holding that the proposed ANDA formulation infringes the claims of that patent. Accordingly, Judge Middlebrooks confirmed that Shire is entitled to an injunction, which he will issue separately, which prohibits the FDA from approving the ANDA formulation until the expiration of the '720 patent. Shire's LIALDA remains the only once-daily mesalamine product indicated for both the induction of remission of mild to moderate ulcerative colitis and for the maintenance of remission of ulcerative colitis. No ANDA's have been approved for generic versions of LIALDA.
Shire LLC Settles INTUNIV Litigation with Actavis and Watson
Apr 26 13
Shire plc announced that its subsidiary, Shire LLC, has settled all pending litigation with Actavis, Inc., Actavis LLC, and Actavis Elizabeth LLC (collectively Actavis) and Watson Laboratories, Inc., Watson Pharma, Inc. and Anda, Inc. (collectively Watson) in connection with Actavis' and Watson's Abbreviated New Drug Applications (ANDAs) for generic versions of Shire's INTUNIV (Registered) (guanfacine hydrochloride) for the treatment of Attention Deficit Hyperactivity Disorder. The settlement provides Actavis with a license to make and market Actavis' generic versions of INTUNIV in the United States on December 1, 2014, or earlier in certain limited circumstances. Such sales will require the payment of a royalty of 25% of gross profits to Shire during the 180 day period of Actavis' exclusivity. The settlement also provides Watson with a license to make and market Watson's generic versions of INTUNIV in the United States 181 days after Actavis' launch of generic INTUNIV, or earlier in certain limited circumstances. To date, the US Food and Drug Administration has granted final approval only to Actavis' ANDA for generic versions of INTUNIV. These litigations were patent infringement lawsuits relating to U.S. patents 6,287,599 (the '599 Patent), 6,811,794 (the '794 Patent), 5,854,290 (which was subsequently dedicated to the public). As part of the settlement, Actavis and Watson have agreed to a consent judgment confirming that their proposed generic products infringe Shire's '599 and '794 Patents and that those two patents are valid and enforceable with respect to those proposed generic products and any other generic version of INTUNIV. The lawsuit against Actavis proceeded to trial in the District Court of Delaware in September 2012 wherein Teva Pharmaceuticals, USA, Inc. was also a defendant. The Delaware court has not issued a decision. The lawsuit against Watson is scheduled for trial to begin on February 10, 2014 wherein Impax Laboratories, Inc. is also a defendant. The agreements, which are effective immediately, will be submitted to the US Federal Trade Commission and Department of Justice for review as required by law.
Depomed Files Lawsuit Against Watson Laboratories, Actavis, and Watson Pharma for Infringement of the Patents Listed in the Orange Book for Glumetza
Mar 1 13
On February 28, 2013, Depomed, Inc. filed a lawsuit in the U.S. District Court for the District of Delaware against Watson Laboratories, Inc., Actavis, Inc., and Watson Pharma, Inc. for infringement of the patents listed in the Orange Book for the prescription product Glumetza® (metformin hydrochloride extended release tablets) 500 mg. The lawsuit is in response to an Abbreviated New Drug Application filed by Watson with the U.S. Food and Drug Administration (FDA) regarding Watson’s intent to market generic versions of Glumetza 500 mg prior to the 2016, 2020, and 2021 expiration dates of the four listed patents (U.S. Patent Nos. 6,340,475, 6,488,962, 6,635,280, and 6,723,340). The lawsuit was commenced within the 45 days required to automatically stay, or bar, the FDA from approving Watson’s ANDA for Glumetza 500 mg for 30 months or until a district court decision that is adverse to the plaintiffs, whichever may occur earlier.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|